Kyoto Prefectural Public University Corporation

Senju Pharmaceutical Co., Ltd.

The Doshisha

Other

Actualeyes Inc.

Kyoto University

Kowa Company Limited

Jcr Pharmaceuticals Co., Ltd.

Corneagen Inc.

Riken Corporation

Santen Pharmaceutical Co., Ltd.

Foundation for Biomedical Research and Innovation at Kobe

Arblast Co., Ltd.

Kabushiki Kaisha Kobe Seiko Sho

Foundation for Biomedical Research and Innovation

Shigeru Kinoshita

Noriko Koizumi

Naoki Okumura

Morio Ueno

Takahiro Nakamura

Norihiko Yokoi

Hiroshi Tanaka

Yuji Sakamoto

Yutaka Mizukusa

Kiwamu Imagawa

Motomu Tanaka

Akihisa Yamamoto

Junji Hamuro

Chie Sotozono

Hiroaki Takahashi

Takayoshi Suzuki

Kenichi Maeda

Osamu Yamamoto

Yoshiki Sasai

Yasuhiko Tabata

Maki Hamaguchi

Kei Tashiro

Noriyuki Okuyama

Munetoyo Toda

Hiroatsu Hirano

Kazuhiko Mori

Takazumi Taniguchi

Hanako Ikeda

Masaaki Kageyama

Yuki Hosoda

Eiji Kurihara

Shuichi Yokoyama

Michio Hagiya

Seiichi Yokoo

Yuuki Hosoda

Satoru Yamagami

Ursula Schloetzer-Schrehardt

Makiko Nakahara

Friedrich E Kruse

Kana Tominaga

Satoshi Kawasaki

Masakazu Nakano

Tomohito Yagi

Yoko Ikeda

Akira Kakizuka

Maho Nagata

Koji Sakai

Takuya Yoshida

Hiroki Watanabe

Norihiko Rm 501 Grand Form Kyoto Karasuma Yokoi

Eiji c/o Arblast Co Ltd Kobe International Business Center Building Kurihara

A cell evaluation method evaluates the quality of a cell population including a plurality of cells. The cell evaluation method comprises: an index calculation step of calculating an index, based on a captured image of the cell population, the index including at least any one of an average distance representing a packing degree of the cells, a spring constant representing a degree of consistency in distances between the cells, and a hexagonal order parameter representing a degree to which an arrangement of the cells resembles a regular hexagon; and an evaluation step of evaluating the cell population, based on the index calculated in the index calculation step.

Cell evaluation method, cell evaluation device, and cell evaluation program

The purpose of the present invention is to provide a method of purification and preparation of cultured corneal endothelial cells, and in particular, to provide cell surface markers for use in corneal endothelial cells not including transformed cells. Provided are cell markers for distinguishing normal cells and transformed cells, in particular normal and transformed corneal endothelium cells. These cell markers relate to specific cell surface markers, for example, to a normal corneal endothelial surface marker such as CD166, and a transformed cell surface marker such as CD73. By using the transformed cell surface marker such as CD73 to remove transformed cells by sorting, it becomes possible to improve purity of a normal cultured corneal endothelium. By using normal corneal endothelial surface marker such as CD166, or by combined use with the transformed cell surface marker, it becomes possible to provide a means for verifying the purity of a prepared corneal endothelium.

Corneal endothelial cell marker

The present invention provides a technique for treating retinal epithelium and/or nerves. More specifically, the present invention is an agent for the treatment or prevention of retinal disease or the like and/or a disease, disorder, or ophthalmological state of the nerves, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with retinal pigment epithelial cells and/or nerve cells. Specifically, the present invention can include laminin 411 (α4β1γ1), laminin 511 (α5β1γ1), laminin 521 (α5β2γ1), or fragments of these.

Treatment of retina and nerve using laminin

The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.

Agent for promoting corneal endothelial cell adhesion

The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.

Corneal endothelium ECM therapeutic medicaments

The present invention provides a technique for treating the cornea. More specifically, the present invention is an agent for the treatment or prevention of a state of corneal endothelial disease, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with corneal endothelial cells. Specifically, the present invention can include laminin 511 (&#x3b1;5&#x3b2;1&#x3b3;1), laminin 521 (&#x3b1;5&#x3b2;2&#x3b3;1), or a fragment of these.

Treatment of cornea using laminin

The present invention provides a method of culturing corneal endothelial cells. More specifically, the present invention provides a composition for culturing or growing corneal endothelial cells, comprising at least one agent consisting of laminins and fragments thereof which express in corneal endothelial cells. Specifically, the present invention can comprise laminin 511 (alpha5 beta1 gamma1) and laminin 512 (alpha5 beta2 gamma 1). The present invention further provides a culture container for corneal endothelial cells, which is coated with the composition of the present invention. Furthermore, the present invention provides a method for culturing corneal endothelial cells comprising the step of using the composition or the container of the present invention to culture the corneal endothelial cells.

Application of laminin to corneal endothelial cell culture

A method for producing an epithelial cell sheet, comprising culturing cells derived from oral mucosal epithelial cells on a substrate in a serum-free medium, wherein the serum-free medium comprises (i) EGF protein or KGF protein, (ii) B-27 supplement, and (iii) a ROCK inhibitor.

Method for producing cultivated epithelial cell sheet

Cell evaluation method, cell evaluation device, and recording medium storing cell evaluation program

The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGF&#x3b2;-signal inhibitor. As a preferred TGF&#x3b2;-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.

Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium

The present invention provides an agent for treating or preventing a disease, a disorder or a condition of a corneal endothelium, said agent comprising a corneal endothelial cell and a myosin II-specific inhibitor. More specifically, the myosin II-specific inhibitor is blebbistatin. The disease, the disorder or the condition is typically a disorder associated with Fuchs endothelial corneal dystrophy or corneal endothelial dysfunction (bullous keratopathy). Also provided is a method for treating or preventing a corneal endothelial disease, said method comprising a step of administering an effective amount of a myosin II-specific inhibitor together with a corneal endothelial cell to a subject.

Combined agent for cell therapy of corneal endothelial cell

Provided is an agent for treating or preventing a corneal endothelial disorder wherein cell proliferation is required. More specifically, provided is an agent for treating or preventing a corneal endothelial disorder, wherein cell proliferation is required, said agent comprising a p38MAP kinase inhibitor. In a preferred embodiment, the corneal endothelial disorder is a wound. In a preferred embodiment, the p38MAP kinase inhibitor is soluble in water. The p38MAP kinase inhibitor may comprise 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580) or a salt thereof.

Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage

[Problem] To provide a method for producing human corneal epithelial sheet, wherein the human corneal epithelial-derived cells obtained by culturing human corneal epithelial cells are cultured on an amnion substrate. [Solution] A method for culturing human corneal epithelial cells using mesenchymal stem cells as the feeder cells; and a method for culturing human corneal epithelial cells using a medium containing a ROCK inhibitor, a phosphodiesterase inhibitor, a MAP kinase inhibitor and a TGF-&#x3b2; receptor inhibitor in various combinations.

Method for producing human corneal epithelium sheet

Growing community of inventors

Kyoto, Japan

Shigeru Kinoshita